You are here

AstraZeneca shares plunge as the firm's lung cancer study fails


ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.

The so-called Mystic study was the most anticipated...

Market voices on: